Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas

NCT02364076 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02364076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02364076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2015
Completion date
December 31, 2021
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thymic carcinoma, thymus cancer, thymus neoplasms